ESR1 and breast cancer: This variant was also significantly associated with odds of ER- and PR- breast cancer using the joint test [ER- OR≥7dpw (95% CI) = 3.92 (0.28, 55.41), OR<7dpw = 0.24 (0.13, 0.44), pjoint = 3.74 × 10−6; PR- OR≥7dpw (95% CI) = 1.77 (0.29, 10.87), OR<7dpw (95% CI) = 0.31 (0.17, 0.55), pjoint = 9.52 × 10–5] (Additional file 1, Table 2).